secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001437749-25-033017
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01, 2.02
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell names Olivier te Boekhorst CEO; board expanded to nine directors
-------------------------------------------------------------------------

- Olivier te Boekhorst started as President and CEO on Nov 1, 2025, succeeding Michael Brigham.
- Board expanded from 7 to 9 directors; te Boekhorst and CFO Timothy Fiori elected as directors.
- Michael Brigham remains board member and Special Advisor to CEO until January 2026.
- CFO Fiori also appointed Secretary and Treasurer.
- Company to host Q3 earnings conference call on Nov 14, 2025 at 9:00 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774925033017/0001437749-25-033017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774925033017/iccc20251103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-033017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer